GlassScriptPhysician profile
Richard M Rayner
NPI 1093770885
$5,710.65
in general payments reported to CMS, 2019-2025
35 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $205 · 2021: $621 · 2022: $643 · 2023: $1,343 · 2024: $1,841 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,740 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,739.81 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,084.14 | 2021-2025 | |
| Novo Nordisk INC | $954.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $839.81 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $664.09 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $376.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $281.61 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $208.55 | 2019-2024 | Vaxelis, Gardasil, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.45 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $126.76 | 2020-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $123.92 | 2019-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $115.80 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $94.63 | 2021-2023 | Trintellix |
| Dexcom, INC. | $73.29 | 2021-2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $51.34 | 2022-2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $50.17 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $49.05 | 2022 | |
| Amgen INC. | $48.51 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.21 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $41.84 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $35.95 | 2024 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $32.42 | 2022-2023 | Gvoke Hypopen |
| Cequr Corporation | $32.42 | 2024-2025 | Cequr Simplicity |
| Sanofi Pasteur INC. | $29.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.54 | 2019 | |
| Allergan, INC. | $24.72 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.07 | 2021 | |
| Ibsa Pharma INC. | $21.17 | 2023 | Tirosint, Licart |
| Otsuka America Pharmaceutical, INC. | $20.90 | 2023 | Rexulti |
| Antares Pharma, INC. | $19.00 | 2024 | Xyosted |
| Phathom Pharmaceuticals, INC. | $17.96 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $16.70 | 2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $15.13 | 2019 | |
| Sumitomo Pharma America, INC. | $14.95 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $13.44 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rayner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.